Pre-Dilatation Versus No Pre-Dilatation for Implantation of a Self-Expanding Valve in All Comers Undergoing TAVR: The DIRECT Trial
The aim of this study was to compare the implantation of a self-expanding valve with or without balloon aortic valvuloplasty (BAV) in an open-label, noninferiority, randomized trial. There are no randomized studies comparing the implantation of a self-expanding valve with (pre-BAV) or without BAV. C...
Gespeichert in:
| Veröffentlicht in: | JACC. Cardiovascular interventions 2019-04, Vol.12 (8), p.767-777 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 777 |
|---|---|
| container_issue | 8 |
| container_start_page | 767 |
| container_title | JACC. Cardiovascular interventions |
| container_volume | 12 |
| creator | Toutouzas, Konstantinos Benetos, Georgios Voudris, Vasilis Drakopoulou, Maria Stathogiannis, Konstantinos Latsios, George Synetos, Andreas Antonopoulos, Alexios Kosmas, Elias Iakovou, Ioannis Katsimagklis, Georgios Mastrokostopoulos, Antonios Moraitis, Sotiris Zeniou, Vicki Danenberg, Haim Vavuranakis, Manolis Tousoulis, Dimitris |
| description | The aim of this study was to compare the implantation of a self-expanding valve with or without balloon aortic valvuloplasty (BAV) in an open-label, noninferiority, randomized trial.
There are no randomized studies comparing the implantation of a self-expanding valve with (pre-BAV) or without BAV.
Consecutive patients with severe aortic stenosis were randomly assigned to undergo transcatheter aortic valve replacement with the use of self-expanding prostheses with (pre-BAV) or without (no-BAV) pre-dilatation. The primary endpoint was device success according to the Valve Academic Research Consortium 2 criteria. Secondary endpoints included periprocedural mortality and stroke, new permanent pacemaker implantation, vascular complications, and 1-year mortality. The trial was scheduled to show noninferiority (Δ = 15%) of the direct versus the pre-BAV approach.
A total of 171 patients were randomized at 4 centers. Of these, 86 underwent transcatheter aortic valve replacement with pre-dilatation and 85 without. Device success was noninferior in the no-BAV group compared with the pre-BAV group (65 of 85 [76.5%] for no-BAV vs. 64 of 86 [74.4%] for pre-BAV; mean difference 2.1%; 90% confidence interval: -8.9% to 13%). In the no-BAV group, 25 patients (29.4%) underwent post-balloon dilatation, and in the pre-BAV group, 13 patients (15.1%) underwent post-balloon dilatation (p = 0.03). Regarding major vascular complications and permanent pacemaker implantation, there was no difference between the 2 groups (log-rank p = 0.49, log-rank p = 0.54). In 1-month completed follow-up for all patients, there was 1 periprocedural stroke (0.5%), without any deaths.
Direct, without balloon pre-dilatation, transcatheter aortic valve replacement with a self-expanding prosthesis system is noninferior to the pre-dilatation procedure. Lower post-dilatation rates were encountered in the group with pre-dilatation. (The Predilatation in Transcatheter Aortic Valve Implantation Trial [DIRECT]; NCT02448927). |
| doi_str_mv | 10.1016/j.jcin.2019.02.005 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2201718399</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2201718399</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-e3bf8f1a9a9b73cae694aed904e37251d44935e3598e00b2390d8b1f71a288723</originalsourceid><addsrcrecordid>eNpdkD1PwzAYhC0kREvhDzAgjywJ_khim60qBSpVgEraNXKaNyWVEwc7QbDyywmiLEwn3T066Q6hC0pCSmhyvQ_326oJGaEqJCwkJD5CYypFEoiExCN06v2ekIQowU7QiBPFZBSxMfp6dhDcVkZ3uqtsgzfgfO_xo8X_gtI6vKhbo5uDYUus8QuYMph_tLopqmaHN9q8A64aPDUGz2w9lOF1U4Db2Z84nW5WNzh9BXy7WM1nKU5dpc0ZOi618XB-0Ala383T2UOwfLpfzKbLoGWUdgHwvJQl1UqrXPCthkRFGgpFIuCCxbSIIsVj4LGSQEjOuCKFzGkpqGZSCsYn6Oq3t3X2rQffZXXlt2CGSWB7n7HhPEElV2pALw9on9dQZK2rau0-s7_f-DcD0G2X</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2201718399</pqid></control><display><type>article</type><title>Pre-Dilatation Versus No Pre-Dilatation for Implantation of a Self-Expanding Valve in All Comers Undergoing TAVR: The DIRECT Trial</title><source>Elsevier ScienceDirect Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><creator>Toutouzas, Konstantinos ; Benetos, Georgios ; Voudris, Vasilis ; Drakopoulou, Maria ; Stathogiannis, Konstantinos ; Latsios, George ; Synetos, Andreas ; Antonopoulos, Alexios ; Kosmas, Elias ; Iakovou, Ioannis ; Katsimagklis, Georgios ; Mastrokostopoulos, Antonios ; Moraitis, Sotiris ; Zeniou, Vicki ; Danenberg, Haim ; Vavuranakis, Manolis ; Tousoulis, Dimitris</creator><creatorcontrib>Toutouzas, Konstantinos ; Benetos, Georgios ; Voudris, Vasilis ; Drakopoulou, Maria ; Stathogiannis, Konstantinos ; Latsios, George ; Synetos, Andreas ; Antonopoulos, Alexios ; Kosmas, Elias ; Iakovou, Ioannis ; Katsimagklis, Georgios ; Mastrokostopoulos, Antonios ; Moraitis, Sotiris ; Zeniou, Vicki ; Danenberg, Haim ; Vavuranakis, Manolis ; Tousoulis, Dimitris</creatorcontrib><description>The aim of this study was to compare the implantation of a self-expanding valve with or without balloon aortic valvuloplasty (BAV) in an open-label, noninferiority, randomized trial.
There are no randomized studies comparing the implantation of a self-expanding valve with (pre-BAV) or without BAV.
Consecutive patients with severe aortic stenosis were randomly assigned to undergo transcatheter aortic valve replacement with the use of self-expanding prostheses with (pre-BAV) or without (no-BAV) pre-dilatation. The primary endpoint was device success according to the Valve Academic Research Consortium 2 criteria. Secondary endpoints included periprocedural mortality and stroke, new permanent pacemaker implantation, vascular complications, and 1-year mortality. The trial was scheduled to show noninferiority (Δ = 15%) of the direct versus the pre-BAV approach.
A total of 171 patients were randomized at 4 centers. Of these, 86 underwent transcatheter aortic valve replacement with pre-dilatation and 85 without. Device success was noninferior in the no-BAV group compared with the pre-BAV group (65 of 85 [76.5%] for no-BAV vs. 64 of 86 [74.4%] for pre-BAV; mean difference 2.1%; 90% confidence interval: -8.9% to 13%). In the no-BAV group, 25 patients (29.4%) underwent post-balloon dilatation, and in the pre-BAV group, 13 patients (15.1%) underwent post-balloon dilatation (p = 0.03). Regarding major vascular complications and permanent pacemaker implantation, there was no difference between the 2 groups (log-rank p = 0.49, log-rank p = 0.54). In 1-month completed follow-up for all patients, there was 1 periprocedural stroke (0.5%), without any deaths.
Direct, without balloon pre-dilatation, transcatheter aortic valve replacement with a self-expanding prosthesis system is noninferior to the pre-dilatation procedure. Lower post-dilatation rates were encountered in the group with pre-dilatation. (The Predilatation in Transcatheter Aortic Valve Implantation Trial [DIRECT]; NCT02448927).</description><identifier>EISSN: 1876-7605</identifier><identifier>DOI: 10.1016/j.jcin.2019.02.005</identifier><identifier>PMID: 30928442</identifier><language>eng</language><publisher>United States</publisher><ispartof>JACC. Cardiovascular interventions, 2019-04, Vol.12 (8), p.767-777</ispartof><rights>Copyright © 2019 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30928442$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Toutouzas, Konstantinos</creatorcontrib><creatorcontrib>Benetos, Georgios</creatorcontrib><creatorcontrib>Voudris, Vasilis</creatorcontrib><creatorcontrib>Drakopoulou, Maria</creatorcontrib><creatorcontrib>Stathogiannis, Konstantinos</creatorcontrib><creatorcontrib>Latsios, George</creatorcontrib><creatorcontrib>Synetos, Andreas</creatorcontrib><creatorcontrib>Antonopoulos, Alexios</creatorcontrib><creatorcontrib>Kosmas, Elias</creatorcontrib><creatorcontrib>Iakovou, Ioannis</creatorcontrib><creatorcontrib>Katsimagklis, Georgios</creatorcontrib><creatorcontrib>Mastrokostopoulos, Antonios</creatorcontrib><creatorcontrib>Moraitis, Sotiris</creatorcontrib><creatorcontrib>Zeniou, Vicki</creatorcontrib><creatorcontrib>Danenberg, Haim</creatorcontrib><creatorcontrib>Vavuranakis, Manolis</creatorcontrib><creatorcontrib>Tousoulis, Dimitris</creatorcontrib><title>Pre-Dilatation Versus No Pre-Dilatation for Implantation of a Self-Expanding Valve in All Comers Undergoing TAVR: The DIRECT Trial</title><title>JACC. Cardiovascular interventions</title><addtitle>JACC Cardiovasc Interv</addtitle><description>The aim of this study was to compare the implantation of a self-expanding valve with or without balloon aortic valvuloplasty (BAV) in an open-label, noninferiority, randomized trial.
There are no randomized studies comparing the implantation of a self-expanding valve with (pre-BAV) or without BAV.
Consecutive patients with severe aortic stenosis were randomly assigned to undergo transcatheter aortic valve replacement with the use of self-expanding prostheses with (pre-BAV) or without (no-BAV) pre-dilatation. The primary endpoint was device success according to the Valve Academic Research Consortium 2 criteria. Secondary endpoints included periprocedural mortality and stroke, new permanent pacemaker implantation, vascular complications, and 1-year mortality. The trial was scheduled to show noninferiority (Δ = 15%) of the direct versus the pre-BAV approach.
A total of 171 patients were randomized at 4 centers. Of these, 86 underwent transcatheter aortic valve replacement with pre-dilatation and 85 without. Device success was noninferior in the no-BAV group compared with the pre-BAV group (65 of 85 [76.5%] for no-BAV vs. 64 of 86 [74.4%] for pre-BAV; mean difference 2.1%; 90% confidence interval: -8.9% to 13%). In the no-BAV group, 25 patients (29.4%) underwent post-balloon dilatation, and in the pre-BAV group, 13 patients (15.1%) underwent post-balloon dilatation (p = 0.03). Regarding major vascular complications and permanent pacemaker implantation, there was no difference between the 2 groups (log-rank p = 0.49, log-rank p = 0.54). In 1-month completed follow-up for all patients, there was 1 periprocedural stroke (0.5%), without any deaths.
Direct, without balloon pre-dilatation, transcatheter aortic valve replacement with a self-expanding prosthesis system is noninferior to the pre-dilatation procedure. Lower post-dilatation rates were encountered in the group with pre-dilatation. (The Predilatation in Transcatheter Aortic Valve Implantation Trial [DIRECT]; NCT02448927).</description><issn>1876-7605</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><recordid>eNpdkD1PwzAYhC0kREvhDzAgjywJ_khim60qBSpVgEraNXKaNyWVEwc7QbDyywmiLEwn3T066Q6hC0pCSmhyvQ_326oJGaEqJCwkJD5CYypFEoiExCN06v2ekIQowU7QiBPFZBSxMfp6dhDcVkZ3uqtsgzfgfO_xo8X_gtI6vKhbo5uDYUus8QuYMph_tLopqmaHN9q8A64aPDUGz2w9lOF1U4Db2Z84nW5WNzh9BXy7WM1nKU5dpc0ZOi618XB-0Ala383T2UOwfLpfzKbLoGWUdgHwvJQl1UqrXPCthkRFGgpFIuCCxbSIIsVj4LGSQEjOuCKFzGkpqGZSCsYn6Oq3t3X2rQffZXXlt2CGSWB7n7HhPEElV2pALw9on9dQZK2rau0-s7_f-DcD0G2X</recordid><startdate>20190422</startdate><enddate>20190422</enddate><creator>Toutouzas, Konstantinos</creator><creator>Benetos, Georgios</creator><creator>Voudris, Vasilis</creator><creator>Drakopoulou, Maria</creator><creator>Stathogiannis, Konstantinos</creator><creator>Latsios, George</creator><creator>Synetos, Andreas</creator><creator>Antonopoulos, Alexios</creator><creator>Kosmas, Elias</creator><creator>Iakovou, Ioannis</creator><creator>Katsimagklis, Georgios</creator><creator>Mastrokostopoulos, Antonios</creator><creator>Moraitis, Sotiris</creator><creator>Zeniou, Vicki</creator><creator>Danenberg, Haim</creator><creator>Vavuranakis, Manolis</creator><creator>Tousoulis, Dimitris</creator><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>20190422</creationdate><title>Pre-Dilatation Versus No Pre-Dilatation for Implantation of a Self-Expanding Valve in All Comers Undergoing TAVR: The DIRECT Trial</title><author>Toutouzas, Konstantinos ; Benetos, Georgios ; Voudris, Vasilis ; Drakopoulou, Maria ; Stathogiannis, Konstantinos ; Latsios, George ; Synetos, Andreas ; Antonopoulos, Alexios ; Kosmas, Elias ; Iakovou, Ioannis ; Katsimagklis, Georgios ; Mastrokostopoulos, Antonios ; Moraitis, Sotiris ; Zeniou, Vicki ; Danenberg, Haim ; Vavuranakis, Manolis ; Tousoulis, Dimitris</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-e3bf8f1a9a9b73cae694aed904e37251d44935e3598e00b2390d8b1f71a288723</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Toutouzas, Konstantinos</creatorcontrib><creatorcontrib>Benetos, Georgios</creatorcontrib><creatorcontrib>Voudris, Vasilis</creatorcontrib><creatorcontrib>Drakopoulou, Maria</creatorcontrib><creatorcontrib>Stathogiannis, Konstantinos</creatorcontrib><creatorcontrib>Latsios, George</creatorcontrib><creatorcontrib>Synetos, Andreas</creatorcontrib><creatorcontrib>Antonopoulos, Alexios</creatorcontrib><creatorcontrib>Kosmas, Elias</creatorcontrib><creatorcontrib>Iakovou, Ioannis</creatorcontrib><creatorcontrib>Katsimagklis, Georgios</creatorcontrib><creatorcontrib>Mastrokostopoulos, Antonios</creatorcontrib><creatorcontrib>Moraitis, Sotiris</creatorcontrib><creatorcontrib>Zeniou, Vicki</creatorcontrib><creatorcontrib>Danenberg, Haim</creatorcontrib><creatorcontrib>Vavuranakis, Manolis</creatorcontrib><creatorcontrib>Tousoulis, Dimitris</creatorcontrib><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>JACC. Cardiovascular interventions</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Toutouzas, Konstantinos</au><au>Benetos, Georgios</au><au>Voudris, Vasilis</au><au>Drakopoulou, Maria</au><au>Stathogiannis, Konstantinos</au><au>Latsios, George</au><au>Synetos, Andreas</au><au>Antonopoulos, Alexios</au><au>Kosmas, Elias</au><au>Iakovou, Ioannis</au><au>Katsimagklis, Georgios</au><au>Mastrokostopoulos, Antonios</au><au>Moraitis, Sotiris</au><au>Zeniou, Vicki</au><au>Danenberg, Haim</au><au>Vavuranakis, Manolis</au><au>Tousoulis, Dimitris</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pre-Dilatation Versus No Pre-Dilatation for Implantation of a Self-Expanding Valve in All Comers Undergoing TAVR: The DIRECT Trial</atitle><jtitle>JACC. Cardiovascular interventions</jtitle><addtitle>JACC Cardiovasc Interv</addtitle><date>2019-04-22</date><risdate>2019</risdate><volume>12</volume><issue>8</issue><spage>767</spage><epage>777</epage><pages>767-777</pages><eissn>1876-7605</eissn><abstract>The aim of this study was to compare the implantation of a self-expanding valve with or without balloon aortic valvuloplasty (BAV) in an open-label, noninferiority, randomized trial.
There are no randomized studies comparing the implantation of a self-expanding valve with (pre-BAV) or without BAV.
Consecutive patients with severe aortic stenosis were randomly assigned to undergo transcatheter aortic valve replacement with the use of self-expanding prostheses with (pre-BAV) or without (no-BAV) pre-dilatation. The primary endpoint was device success according to the Valve Academic Research Consortium 2 criteria. Secondary endpoints included periprocedural mortality and stroke, new permanent pacemaker implantation, vascular complications, and 1-year mortality. The trial was scheduled to show noninferiority (Δ = 15%) of the direct versus the pre-BAV approach.
A total of 171 patients were randomized at 4 centers. Of these, 86 underwent transcatheter aortic valve replacement with pre-dilatation and 85 without. Device success was noninferior in the no-BAV group compared with the pre-BAV group (65 of 85 [76.5%] for no-BAV vs. 64 of 86 [74.4%] for pre-BAV; mean difference 2.1%; 90% confidence interval: -8.9% to 13%). In the no-BAV group, 25 patients (29.4%) underwent post-balloon dilatation, and in the pre-BAV group, 13 patients (15.1%) underwent post-balloon dilatation (p = 0.03). Regarding major vascular complications and permanent pacemaker implantation, there was no difference between the 2 groups (log-rank p = 0.49, log-rank p = 0.54). In 1-month completed follow-up for all patients, there was 1 periprocedural stroke (0.5%), without any deaths.
Direct, without balloon pre-dilatation, transcatheter aortic valve replacement with a self-expanding prosthesis system is noninferior to the pre-dilatation procedure. Lower post-dilatation rates were encountered in the group with pre-dilatation. (The Predilatation in Transcatheter Aortic Valve Implantation Trial [DIRECT]; NCT02448927).</abstract><cop>United States</cop><pmid>30928442</pmid><doi>10.1016/j.jcin.2019.02.005</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 1876-7605 |
| ispartof | JACC. Cardiovascular interventions, 2019-04, Vol.12 (8), p.767-777 |
| issn | 1876-7605 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2201718399 |
| source | Elsevier ScienceDirect Journals; EZB-FREE-00999 freely available EZB journals |
| title | Pre-Dilatation Versus No Pre-Dilatation for Implantation of a Self-Expanding Valve in All Comers Undergoing TAVR: The DIRECT Trial |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-30T16%3A34%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pre-Dilatation%20Versus%20No%20Pre-Dilatation%20for%20Implantation%20of%20a%20Self-Expanding%20Valve%20in%20All%20Comers%20Undergoing%20TAVR:%20The%20DIRECT%20Trial&rft.jtitle=JACC.%20Cardiovascular%20interventions&rft.au=Toutouzas,%20Konstantinos&rft.date=2019-04-22&rft.volume=12&rft.issue=8&rft.spage=767&rft.epage=777&rft.pages=767-777&rft.eissn=1876-7605&rft_id=info:doi/10.1016/j.jcin.2019.02.005&rft_dat=%3Cproquest_pubme%3E2201718399%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2201718399&rft_id=info:pmid/30928442&rfr_iscdi=true |